Syndax reports Q4 EPS ($1.10) vs ($1.00) last year

Reports Q4 revenue $7.68M vs $0 last year. “We are off to a strong start with the U.S. launch of Revuforj and are very encouraged by the early patient demand, breadth of prescribing, and coverage from payers. Our early results are consistent with the high unmet need in R/R KMT2A-rearranged acute leukemia and reflect strong execution across our entire organization,” said Michael A. Metzger, Chief Executive Officer. “With two first-in-class medicines on the market that address major unmet needs and a robust development strategy underway for expansion, Syndax (SNDX) is well-positioned to unlock the multi-billion-dollar potential of both medicines.”